Low myocardial protein kinase G activity in heart failure with preserved ejection fraction.

Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction. Circulation (2014) 2.79

Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin. Circulation (2015) 1.96

Effects of sildenafil on ventricular and vascular function in heart failure with preserved ejection fraction. Circ Heart Fail (2015) 1.69

Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease. Nature (2015) 1.65

Heart failure with preserved ejection fraction: mechanisms, clinical features, and therapies. Circ Res (2014) 1.56

Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction. J Am Coll Cardiol (2014) 1.27

New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. Eur Heart J (2014) 1.25

Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap. Circulation (2016) 1.14

Longitudinal changes in left ventricular stiffness: a community-based study. Circ Heart Fail (2013) 1.09

Acute hemodynamic effects of riociguat in patients with pulmonary hypertension associated with diastolic heart failure (DILATE-1): a randomized, double-blind, placebo-controlled, single-dose study. Chest (2014) 1.06

The cGMP signaling pathway as a therapeutic target in heart failure with preserved ejection fraction. J Am Heart Assoc (2013) 0.98

Heart failure with preserved ejection fraction in the elderly: scope of the problem. J Mol Cell Cardiol (2015) 0.93

Understanding heart failure with preserved ejection fraction: where are we today? Neth Heart J (2016) 0.87

Nitrate's effect on activity tolerance in heart failure with preserved ejection fraction trial: rationale and design. Circ Heart Fail (2015) 0.87

Heart failure with preserved ejection fraction: emerging drug strategies. J Cardiovasc Pharmacol (2013) 0.87

The role of titin and extracellular matrix remodelling in heart failure with preserved ejection fraction. Neth Heart J (2016) 0.86

Pharmacokinetics and Pharmacodynamics of Inorganic Nitrate in Heart Failure With Preserved Ejection Fraction. Circ Res (2016) 0.85

Is enhancing cGMP-PKG signalling a promising therapeutic target for heart failure with preserved ejection fraction? Neth Heart J (2016) 0.83

Heart failure with preserved ejection fraction. Pflugers Arch (2014) 0.82

Cardiac NO signalling in the metabolic syndrome. Br J Pharmacol (2014) 0.82

Isosorbide Dinitrate, With or Without Hydralazine, Does Not Reduce Wave Reflections, Left Ventricular Hypertrophy, or Myocardial Fibrosis in Patients With Heart Failure With Preserved Ejection Fraction. J Am Heart Assoc (2017) 0.82

Current treatment of heart failure with preserved ejection fraction: should we add life to the remaining years or add years to the remaining life? Cardiol Res Pract (2013) 0.81

Titin mutations: the fall of Goliath. Heart Fail Rev (2015) 0.81

G protein-coupled receptor 35: an emerging target in inflammatory and cardiovascular disease. Front Pharmacol (2015) 0.81

New insights in (inter)cellular mechanisms by heart failure with preserved ejection fraction. Curr Heart Fail Rep (2014) 0.80

Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study. Eur Heart J (2017) 0.80

Acute heart failure with preserved ejection fraction: unique patient characteristics and targets for therapy. Curr Heart Fail Rep (2013) 0.80

cGMP: transition from bench to bedside: a report of the 6th International Conference on cGMP Generators, Effectors and Therapeutic Implications. Naunyn Schmiedebergs Arch Pharmacol (2014) 0.79

Emerging importance of oxidative stress in regulating striated muscle elasticity. J Muscle Res Cell Motil (2014) 0.79

Protein kinase G I and heart failure: Shifting focus from vascular unloading to direct myocardial antiremodeling effects. Circ Heart Fail (2013) 0.78

Prevention of the development of heart failure with preserved ejection fraction by the phosphodiesterase-5A inhibitor vardenafil in rats with type 2 diabetes. Eur J Heart Fail (2016) 0.78

Growing Evidence Linking Microvascular Dysfunction With Heart Failure With Preserved Ejection Fraction. J Am Heart Assoc (2016) 0.78

Inflammation and oxidative stress caused by nitric oxide synthase uncoupling might lead to left ventricular diastolic and systolic dysfunction in patients with hypertension. J Geriatr Cardiol (2015) 0.78

Breakthrough in heart failure with preserved ejection fraction: are we there yet? Korean J Intern Med (2015) 0.78

Advances in the pharmacotherapy of chronic heart failure with preserved ejection fraction: an ideal opportunity for precision medicine. Expert Opin Pharmacother (2017) 0.78

Saxagliptin and Tadalafil Differentially Alter Cyclic Guanosine Monophosphate (cGMP) Signaling and Left Ventricular Function in Aortic-Banded Mini-Swine. J Am Heart Assoc (2016) 0.77

Effect of Heart Failure With Preserved Ejection Fraction on Nitric Oxide Metabolites. Am J Cardiol (2016) 0.77

Potential Expanded Indications for Neprilysin Inhibitors. Curr Heart Fail Rep (2017) 0.76

Old dog, new tricks: novel cardiac targets and stress regulation by protein kinase G. Cardiovasc Res (2016) 0.76

Heart failure: a PKGarious balancing act. Circulation (2012) 0.76

Sodium restriction in heart failure: benefit or harm? Curr Treat Options Cardiovasc Med (2014) 0.75

Update on heart failure with preserved ejection fraction. Curr Cardiovasc Risk Rep (2013) 0.75

Cell- and molecular-level mechanisms contributing to diastolic dysfunction in HFpEF. J Appl Physiol (1985) (2015) 0.75

Alternative Splicing of Titin Restores Diastolic Function in an HFpEF-Like Genetic Murine Model (TtnΔIAjxn). Circ Res (2016) 0.75

Impaired Myocardial Bioenergetics in HFpEF and the Role of Antioxidants. Open Cardiovasc Med J (2016) 0.75

Simvastatin Promotes Cardiac Myocyte Relaxation in Association with Phosphorylation of Troponin I. Front Pharmacol (2017) 0.75

Apocynin influence on oxidative stress and cardiac remodeling of spontaneously hypertensive rats with diabetes mellitus. Cardiovasc Diabetol (2016) 0.75

Cardiac structural remodeling in hypertensive cardiomyopathy. Hypertens Res (2016) 0.75

A change of heart: oxidative stress in governing muscle function? Biophys Rev (2015) 0.75

Heart Failure, Left Ventricular Remodeling, and Circulating Nitric Oxide Metabolites. J Am Heart Assoc (2016) 0.75

An observational study of the association among interatrial adiposity by computed tomography measure, insulin resistance, and left atrial electromechanical disturbances in heart failure. Medicine (Baltimore) (2016) 0.75

Left Ventricular Diastolic Dysfunction in Ischemic Stroke: Functional and Vascular Outcomes. J Stroke (2016) 0.75

Heart failure with preserved ejection fraction: a nephrologist-directed primer. Heart Fail Rev (2017) 0.75

Current Perspectives on Systemic Hypertension in Heart Failure with Preserved Ejection Fraction. Curr Hypertens Rep (2017) 0.75

INDIE-HFpEF (Inorganic Nitrite Delivery to Improve Exercise Capacity in Heart Failure With Preserved Ejection Fraction): Rationale and Design. Circ Heart Fail (2017) 0.75

Targeting Endothelial Function to Treat Heart Failure with Preserved Ejection Fraction: The Promise of Exercise Training. Oxid Med Cell Longev (2017) 0.75

Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2011) 23.50

How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J (2007) 10.38

Early invasive versus selectively invasive management for acute coronary syndromes. N Engl J Med (2005) 7.80

Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet (2013) 7.54

Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med (2011) 7.30

Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J (2003) 4.70

Myocardial infarction accelerates atherosclerosis. Nature (2012) 4.48

Clinical trial registration--looking back and moving ahead. N Engl J Med (2007) 4.07

Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension. Eur Heart J (2007) 3.87

Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J (2010) 3.62

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet (2004) 3.57

B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction. J Am Coll Cardiol (2013) 3.54

Aortic stenosis. Lancet (2009) 3.37

Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation (2008) 3.25

Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension. Circulation (2007) 3.12

Myocardial structure and function differ in systolic and diastolic heart failure. Circulation (2006) 3.11

Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet (2002) 2.85

Pre-hospital triage for primary angioplasty: direct referral to the intervention center versus interhospital transport. JACC Cardiovasc Interv (2010) 2.77

Relationship between nonsustained ventricular tachycardia after non-ST-elevation acute coronary syndrome and sudden cardiac death: observations from the metabolic efficiency with ranolazine for less ischemia in non-ST-elevation acute coronary syndrome-thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation (2010) 2.76

Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation (2007) 2.64

Familial sudden death is an important risk factor for primary ventricular fibrillation: a case-control study in acute myocardial infarction patients. Circulation (2006) 2.63

Dysregulated renin-angiotensin-aldosterone system contributes to pulmonary arterial hypertension. Am J Respir Crit Care Med (2012) 2.52

Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial. JAMA (2004) 2.46

Cardiomyocyte stiffness in diastolic heart failure. Circulation (2005) 2.43

Ultrasound and microbubble-targeted delivery of macromolecules is regulated by induction of endocytosis and pore formation. Circ Res (2009) 2.41

New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper. J Am Coll Cardiol (2012) 2.41

Peripartum cardiomyopathy as a part of familial dilated cardiomyopathy. Circulation (2010) 2.41

PET/MRI of inflammation in myocardial infarction. J Am Coll Cardiol (2012) 2.39

What mechanisms underlie diastolic dysfunction in heart failure? Circ Res (2004) 2.36

Early statin initiation and outcomes in patients with acute coronary syndromes. JAMA (2002) 2.23

Attenuation of toll-like receptor 2-mediated innate immune response in patients with alcoholic chronic liver disease. Liver Int (2010) 2.20

Long-term outcome after an early invasive versus selective invasive treatment strategy in patients with non-ST-elevation acute coronary syndrome and elevated cardiac troponin T (the ICTUS trial): a follow-up study. Lancet (2007) 2.01

Cardiac myosin-binding protein C mutations and hypertrophic cardiomyopathy: haploinsufficiency, deranged phosphorylation, and cardiomyocyte dysfunction. Circulation (2009) 2.01

Hypophosphorylation of the Stiff N2B titin isoform raises cardiomyocyte resting tension in failing human myocardium. Circ Res (2009) 1.99

Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry. PLoS One (2013) 1.97

Clinical trial registration. BMJ (2007) 1.95

Clinical trial registration: looking back and moving ahead. Croat Med J (2007) 1.89

Monocyte subset accumulation in the human heart following acute myocardial infarction and the role of the spleen as monocyte reservoir. Eur Heart J (2013) 1.83

Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J (2010) 1.82

Reactive oxygen species-induced stimulation of 5'AMP-activated protein kinase mediates sevoflurane-induced cardioprotection. Circulation (2009) 1.80

In utero meconium exposure increases spinal cord necrosis in a rat model of myelomeningocele. J Pediatr Surg (2002) 1.80

Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction. Eur Heart J (2007) 1.76

Right ventricular diastolic dysfunction and the acute effects of sildenafil in pulmonary hypertension patients. Chest (2007) 1.74

Anticoagulants in heart disease: current status and perspectives. Eur Heart J (2007) 1.73

Early exercise training normalizes myofilament function and attenuates left ventricular pump dysfunction in mice with a large myocardial infarction. Circ Res (2007) 1.71

Clinical trial registration: looking back and moving ahead. Ann Intern Med (2007) 1.71

Left ventricular torsion: an expanding role in the analysis of myocardial dysfunction. JACC Cardiovasc Imaging (2009) 1.68

Analysis of cardiac myosin binding protein-C phosphorylation in human heart muscle. J Mol Cell Cardiol (2010) 1.67

Multiple myocardial crypts on modified long-axis view are a specific finding in pre-hypertrophic HCM mutation carriers. Eur Heart J Cardiovasc Imaging (2012) 1.66

Finapres arterial pulse wave analysis with Modelflow is not a reliable non-invasive method for assessment of cardiac output. Clin Sci (Lond) (2002) 1.62

C-reactive protein and the risk of cardiovascular mortality. Am J Med (2003) 1.62

Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail (2009) 1.61

Diabetic cardiomyopathy: understanding the molecular and cellular basis to progress in diagnosis and treatment. Heart Fail Rev (2012) 1.61

Nitric oxide's role in the heart: control of beating or breathing? Am J Physiol Heart Circ Physiol (2004) 1.60

High dose adenosine for suboptimal myocardial reperfusion after primary PCI: A randomized placebo-controlled pilot study. Catheter Cardiovasc Interv (2008) 1.57

The influence of clinical characteristics, laboratory and inflammatory markers on 'high on-treatment platelet reactivity' as measured with different platelet function tests. Thromb Haemost (2009) 1.56

Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus. Circulation (2009) 1.55

Antiplatelet treatment for prevention of cerebrovascular events in patients with vascular diseases: a systematic review and meta-analysis. Stroke (2013) 1.53

Diaphragm muscle fiber weakness and ubiquitin-proteasome activation in critically ill patients. Am J Respir Crit Care Med (2015) 1.52

Meconium dependence of bowel damage in gastroschisis. J Pediatr Surg (2002) 1.50

Complement factor C5a as mast cell activator mediates vascular remodelling in vein graft disease. Cardiovasc Res (2012) 1.49

Prehospital versus hospital fibrinolytic therapy using automated versus cardiologist electrocardiographic diagnosis of myocardial infarction: abortion of myocardial infarction and unjustified fibrinolytic therapy. Am Heart J (2004) 1.48

Sarcomeric dysfunction in heart failure. Cardiovasc Res (2007) 1.46

N-terminal pro-brain natriuretic peptide for additional risk stratification in patients with non-ST-elevation acute coronary syndrome and an elevated troponin T: an Invasive versus Conservative Treatment in Unstable coronary Syndromes (ICTUS) substudy. Am Heart J (2007) 1.46

Improvement in cardiac sympathetic nerve activity in responders to resynchronization therapy. Europace (2008) 1.46

Antithrombotic treatment for patients on oral anticoagulation undergoing coronary stenting: a review of the available evidence and practical suggestions for the clinician. Int J Cardiol (2007) 1.45

Drug-eluting stents versus bare-metal stents in diabetic patients with ST-segment elevation acute myocardial infarction: a pooled analysis of individual patient data from seven randomized trials. Rev Esp Cardiol (2009) 1.45

Perturbed length-dependent activation in human hypertrophic cardiomyopathy with missense sarcomeric gene mutations. Circ Res (2013) 1.44

Reperfusion therapy starts in the ambulance. Circulation (2006) 1.44

Impaired left ventricular filling due to right-to-left ventricular interaction in patients with pulmonary arterial hypertension. Am J Physiol Heart Circ Physiol (2005) 1.43